PVLA
NASDAQ · Biotechnology
Palvella Therapeutics Inc
$175.92
+19.07 (+12.16%)
Open$158.01
Previous Close$156.85
Day High$176.94
Day Low$156.54
52W High$166.73
52W Low$72.23
Volume—
Avg Volume277.8K
Market Cap2.53B
P/E Ratio—
EPS$-4.82
SectorBiotechnology
Analyst Ratings
Strong Buy
22 analysts
Price Target
-70.0% upside
Current
$175.92
$175.92
Target
$52.81
$52.81
$42.56
$52.81 avg
$76.13
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 547.08M | 482.27M | 158.95M |
| Net Income | -109,696,002 | -87,029,620 | 26.26M |
| Profit Margin | -57.3% | -54.5% | 16.5% |
| EBITDA | -90,337,714 | -75,653,057 | 46.23M |
| Free Cash Flow | — | — | 10.92M |
| Rev Growth | +13.4% | +13.4% | +20.5% |
| Debt/Equity | 0.63 | 0.63 | 0.49 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $291.31 | +1.07% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $460.42 | +0.03% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $166.89 | -0.41% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $547.09 | +0.85% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $904.35 | +0.16% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $155.94 | -0.46% | 7.7 | 20.98B |